Related references
Note: Only part of the references are listed.Predominant role of innate pro-inflammatory cytokines in vitiligo disease
Nasser Gholijani et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2020)
Anti-inflammatory modulation of human myeloid-derived dendritic cell subsets by lenalidomide
Kazuyo Yamamoto et al.
IMMUNOLOGY LETTERS (2019)
Cytokines: the yin and yang of vitiligo pathogenesis
Mala Singh et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2019)
Vitiligo Skin Is Imprinted with Resident Memory CD8 T Cells Expressing CXCR3
Katia Boniface et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation
Karel Fostier et al.
Oncotarget (2018)
Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy
Katia Boniface et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2018)
Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity
James P. Strassner et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
New discoveries in the pathogenesis and classification of vitiligo
Michelle Rodrigues et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Increased systemic and epidermal levels of IL-17A and IL-1β promotes progression of non-segmental vitiligo
Supriya Bhardwaj et al.
CYTOKINE (2017)
Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease
Belen Lopez-Millan et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2017)
Interleukin 10 protects primary melanocyte by activation of Stat-3 and PI3K/Akt/NF-κB signaling pathways
Jia Zhou et al.
CYTOKINE (2016)
Interferon-gamma Inhibits Melanogenesis and Induces Apoptosis in Melanocytes: A Pivotal Role of CD8+ Cytotoxic T Lymphocytes in Vitiligo
Lili Yang et al.
ACTA DERMATO-VENEREOLOGICA (2015)
Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo
K. C. Webb et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Differential expression of mRNA for T-bet and GATA-3 transcription factors in peripheral blood mononuclear cells of patients with vitiligo
A. Nouri-Koupaee et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2015)
Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease
Elvira Valera et al.
JOURNAL OF NEUROINFLAMMATION (2015)
Association of IFN-γ : IL-10 Cytokine Ratio with Nonsegmental Vitiligo Pathogenesis
Yaswanth Ala et al.
AUTOIMMUNE DISEASES (2015)
The Role of Tumor Necrosis Factor-α in the Pathogenesis of Vitiligo
Carlos R. Camara-Lemarroy et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2013)
Melanocyte-specific CD8+ T cells are associated with epidermal depigmentation in a novel mouse model of vitiligo
S. You et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2013)
Pharmacokinetics and Tissue Disposition of Lenalidomide in Mice
Darlene M. Rozewski et al.
AAPS JOURNAL (2012)
A Mouse Model of Vitiligo with Focused Epidermal Depigmentation Requires IFN-γ for Autoreactive CD8+ T-Cell Accumulation in the Skin
John E. Harris et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
Systemic analyses of immunophenotypes of peripheral T cells in non-segmental vitiligo: implication of defective natural killer T cells
Li Zhou et al.
PIGMENT CELL & MELANOMA RESEARCH (2012)
Dysregulation of melanocyte function by Th17-related cytokines: significance of Th17 cell infiltration in autoimmune vitiligo vulgaris
Yorihisa Kotobuki et al.
PIGMENT CELL & MELANOMA RESEARCH (2012)
Increased Tumor Necrosis Factor (TNF)-α and Its Promoter Polymorphisms Correlate with Disease Progression and Higher Susceptibility towards Vitiligo
Naresh C. Laddha et al.
PLOS ONE (2012)
Hair repigmentation associated with the use of lenalidomide: Graying may not be an irreversible process!
Constantin A Dasanu et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2012)
Serum concentration of IL-6, IL-2, TNF-α, and IFNγ in Vitiligo patients
Suman Singh et al.
INDIAN JOURNAL OF DERMATOLOGY (2012)
Lenalidomide A Review of its Use in the Treatment of Relapsed or Refractory Multiple Myeloma
Lesley J. Scott et al.
DRUGS (2011)
A study of blood CD3+, CD4+, and CD8+ T cell levels and CD4+:CD8+ ratio in vitiligo patients
P. K. Nigam et al.
INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY (2011)
Lenalidomide down regulates the production of interferon-gamma and the expression of inhibitory cytotoxic receptors of human Natural Killer cells
Nicolas Dauguet et al.
CELLULAR IMMUNOLOGY (2010)
Analysis of interleukin-10 levels in lesions of vitiligo following treatment with topical tacrolimus
Z. A. Taher et al.
BRITISH JOURNAL OF DERMATOLOGY (2009)
Mechanism of action of lenalidomide in hematological malignancies
Venumadhav Kotla et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2009)
Vitiligo puzzle: the pieces fall in place
Wiete Westerhof et al.
PIGMENT CELL RESEARCH (2007)
Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents
JB Bartlett et al.
NATURE REVIEWS CANCER (2004)
Topical tacrolimus therapy for vitiligio: Therapeutic responses and skin messenger RNA expression of proinflammatory cytokines
PE Grimes et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2004)
Autoimmune aspects of depigmentation in vitiligo
IC Le Poole et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS (2004)
Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients
RL Mandelcorn-Monson et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2003)
Increased interleukin-6 and granulocyte-macrophage clony stimulating factor levels in the sera of patients with non-segmental vitiligo
CX Tu et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2003)
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
PG Richardson et al.
BLOOD (2002)
New insights into the pathogenesis of vitiligo: Imbalance of epidermal cytokines at sites of lesions
S Moretti et al.
PIGMENT CELL RESEARCH (2002)
Direct evidence to support the role of antigen-specific CD8+ T cells in melanoma-associated vitiligo
FA Le Gal et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2001)
Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and Gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers:: the role of cellular immunity in the etiopathogenesis of vitiligo
B Palermo et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2001)
HLA-A2 restricted, melanocyte-specific CD8+ T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1
KS Lang et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2001)
Share Paper
